Skip to main content
logo
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
4.620
-0.540 (-10.47%)
At close: Nov 5, 2026, 4:00 PM EST
4.620
0.00 (0.00%)
After-hours: Nov 5, 2026, 4:38 PM EST

Kyverna Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----7.035.66
Revenue Growth
----24.20%-
Gross Profit
----49.92-21.38-20.2
Operating Income
-158.93-169.83-142.6-62.41-29.38-26.35
Net Income
-152.64-161.31-127.48-60.37-28.89-26.35
Earnings Per Share
-2.88-3.64-3.33-89.61-63.43-99.10
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
199.43279.25285.9857.5451.3276.07
Total Debt
3329.038.249.0810.565.56
Net Cash (Debt)
166.43250.22277.7448.4640.7670.51
Net Cash Growth
-19.11%-9.91%473.08%18.91%-42.20%-
Net Cash Per Share
3.145.657.2571.9589.48265.19

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-158.75-153.71-114.25-52.41-36.11-22.16
Capital Expenditures
-0.29-0.01-2.21-0.62-0.77-1.29
Free Cash Flow
-159.05-153.72-116.46-53.03-36.88-23.44
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-----418.28%-465.81%
Pretax Margin
-----411.29%-465.88%
Profit Margin
-----411.29%-465.88%
FCF Margin
-----525.00%-414.50%

Valuation
Selected indicators aren't available for this stock.